BioMimetic sees FDA panel detractors for bone graft system

05/12/2011 | Wall Street Journal, The

An FDA advisory panel narrowly recommended the approval of BioMimetic Therapeutics' Augment bone graft system, which is designed for use in foot and ankle fusion surgeries. Meanwhile, BioMimetic officials responded to a negative review by FDA staff, saying there "was absolutely no data" to indicate that its device causes cancer.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD